Mineralys Therapeutics, Inc. 4

Chief Medical Officer Rodman David Malcom exercised 2,171 stock options at $0.16 and sold 2,171 Mineralys Therapeutics (MLYS) common shares at $30.30 on 2026-07-09 under a Rule 10b5-1 plan.

On July 9, 2026, Mineralys Therapeutics, Inc. Chief Medical Officer Rodman David Malcom exercised 2,171 stock options for common stock at an exercise price of $0.16 per share, acquiring 2,171 shares, and on the same day sold 2,171 shares of common stock at $30.30 per share under a Rule 10b5-1 trading plan, resulting in a net change that appears primarily administrative rather than an open-market position increase. Following these transactions, he directly owned 57,733 shares of common stock, which includes 638 shares previously acquired through the company’s 2023 Employee Stock Purchase Plan that had not been reported earlier. The exercised option was from a grant vesting 25% after one year and the remainder in 36 monthly installments, and the disclosed option expiration date is February 9, 2033. Based on the reported sale price as a proxy for current value, his post-transaction holdings are worth roughly $1.75 million.

Filing Facts

CIK

1933414

Ticker

MLYS

Form

4

Source Type

fda

Accession

0001672659-26-000033

Alert Tier

6